Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4752W HIGH $7.60
Volume
77.30 K
Value Traded
402.01 K
Short % Float
8.62%
-8.14%Week
-63.98%1 Month
+251.11%3 Month
+104.31%6 Month
-98.63%5 Year
-99.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.56 M
EPS (TTM)
-7.36
P/E Ratio
-
Ent. Value
-2.52 M
Total Shares
3.19 M
Float Shares
2.48 M
Insiders
22.25%
Institutions
21.82%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LGVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Longeveron Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Longeveron Inc.
394Total events
9Upcoming
72Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Longeveron to participate in 13th Aging Research and Drug Discovery Meeting (ARDD)
▼Topline ReadoutLomecel-BClinical Data
Longeveron announces topline results from ELPIS II Phase 2b trial of laromestrocel in HLHS
Hypoplastic Left Heart Syndrome (HLHS)source ↗
▼Primary Endpoint MissedLomecel-BClinical Data
ELPIS II did not meet primary endpoint of improvement in RVEF at Month 12
Hypoplastic Left Heart Syndrome (HLHS)source ↗
▲Safety Data UpdateLomecel-BClinical Data
Laromestrocel demonstrated favorable safety and tolerability profile in ELPIS II
Hypoplastic Left Heart Syndrome (HLHS)source ↗
▲PreprintLomecel-BPresentation
Preprint of post-hoc exploratory analysis of CLEAR MIND Phase 2a data in Alzheimer's disease
Alzheimer's Diseasesource ↗
▲Milestone PaymentCorporate
Selected as Finalist Team in XPRIZE Healthspan and will receive $1.0 million Milestone 2 Award
▲Grant / FundingLomecel-BCorporate
Longeveron selected as XPRIZE Healthspan Milestone 2 Awardee, receiving $1,000,000
Aging-related Frailtysource ↗
◆Poster PresentationLomecel-BPresentation
Poster presentation at AAIC 2026 on laromestrocel stabilizing brain inflammation in Alzheimer's disease
Alzheimer's diseasesource ↗
◆Topline ReadoutLomecel-BClinical Data
Top-line results from Phase 2b trial of laromestrocel in HLHS
Hypoplastic Left Heart Syndrome (HLHS)source ↗
◆Timing GuidanceLomecel-BPresentation
Anticipated pivotal Phase 2b ELPIS II topline data readout in 3Q26
Hypoplastic Left Heart Syndrome (HLHS)source ↗
◆Topline ReadoutlaromestorcelClinical Data
Top-line data expected approximately 13 months from June 2025
hypoplastic left heart syndrome (HLHS)source ↗
▲Poster PresentationLomecel-BPresentation
Poster presentation at AAIC 2026 on additional analysis of Phase 2a data in mild AD
Alzheimer's diseasesource ↗
◆Oral PresentationLomecel-BPresentation
Corporate presentation at BIO International Convention 2026
▲Enrollment CompleteLomecel-BTrial
Completed enrollment for Phase 2b ELPIS II trial in HLHS
Hypoplastic Left Heart Syndromesource ↗
▲Other Regulator MilestoneEx-US Regulatory
Granted Small or Medium-sized Enterprise (SME) status by EMA in June
▲DSMB ReviewLomecel-BTrial
DMC positive review and recommendation to complete Phase 2b trial
hypoplastic left heart syndrome (HLHS)source ↗
▲DSMB ReviewLomecel-BTrial
DMC completed final prespecified data review for ELPIS II, no safety concerns, approved study to continue
hypoplastic left heart syndrome (HLHS)source ↗
▲Patent GrantedIP / Competition
China patent granted for potency assay methods for assessing human MSCs
◆FDA Feedback ReceivedLomecel-BFDA Meeting
FDA meeting summary received in late April 2026
hypoplastic left heart syndrome (HLHS)source ↗
▲Patent GrantedIP / Competition
China National Intellectual Property Administration granted patent covering potency assay methods for MSCs
▼Equity OfferingCorporate
Closed private placement of up to $30 million, $15 million funded initially, in March 2026
●Type C MeetingLomecel-BFDA Meeting
FDA Type C meeting held in late March 2026 focused on ELPIS II trial and upcoming data readout
hypoplastic left heart syndrome (HLHS)source ↗
◆Management ChangeCorporate
Resignation of Richard Kender from Board of Directors in March 2026
▲Full ResultsLomecel-BClinical Data
Phase 2b results published in Cell Stem Cell
age-related frailtysource ↗
▲PRV GrantedDesignation
Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
▲PublicationLomecel-BPresentation
Phase 2b laromestrocel frailty results published in Cell Stem Cell
Aging-related Frailtysource ↗
▲Patent GrantedIP / Competition
Japan Patent No. 2022-563984 granted for potency assay methods for assessing MSCs
◆Oral PresentationPresentation
Participation in StartUp Health Apollo House during JPM Healthcare Week 2026
▲Patent GrantedLomecel-BIP / Competition
JPO granted patent for potency assay methods for MSCs in January 2026
▲Patent GrantedIP / Competition
USPTO granted U.S. Patent No. 12,496,316 for treatment of female sexual dysfunction using proprietary MSCs
female sexual dysfunctionsource ↗
◆Oral PresentationPresentation
Dr. Joshua Hare and Dr. Nataliya Agafonova speak at CVCT Forum
▲Patent GrantedLomecel-BIP / Competition
Canadian patent granted for method of using laromestrocel to treat aging-related frailty and NIDCM
aging-related frailty; non-ischemic dilated cardiomyopathysource ↗
◆Poster PresentationLomecel-BPresentation
Poster presentation of MRI biomarker data linking neuroinflammation to clinical outcomes at CTAD 2025
Mild Alzheimer's diseasesource ↗
●Oral PresentationLomecel-BPresentation
Laromestrocel data from CLEAR MIND presented at CTAD 2025 in December 2025
Alzheimer's diseasesource ↗
▲Patent GrantedLomecel-BIP / Competition
USPTO granted patent for administration of laromestrocel for female sexual dysfunction in December 2025
Sexual dysfunctionsource ↗
◆Topline ReadoutLomecel-BClinical Data
Data read-out from Phase 2 HLHS trial
Hypoplastic Left Heart Syndrome (HLHS)source ↗
▲Patent GrantedLomecel-BIP / Competition
USPTO granted U.S. Patent No. 12,465,620 for method of treating aging frailty with MSCs
aging-related frailtysource ↗
▲Patent GrantedLomecel-BIP / Competition
USPTO granted patent for administration of laromestrocel for Aging-related Frailty in November 2025
Aging-related Frailtysource ↗
Past FDA Catalysts and PDUFA Decisions
How LGVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-31 | laromestrocel (Lomecel-B®) | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 63%
Micro Cap(rank 415 of 658)
Percentile Rank
Longeveron Inc. faces pipeline headwinds (32/100), with $339M risk-adjusted pipeline value, led by Allogeneic MSC in Mild Alzheimer's Disease (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Allogeneic MSC Small moleculeCompletedNCT05233774 | Mild Alzheimer's Disease | Phase 2 | COMPLETED | 50 | Sep 29, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every LGVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| laromestrocel Fast TrackRMATOrphan+1 | aging-related frailty | Phase 2b | 2026-09-30 | intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placeboRead More | Longeveron to Participate in Three Longevity/Aging Investment ConferencesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hare JoshuaDirector, Officer (Chief Scientific Officer), 10% Owner | Grant/Award | 600,000 1,321,796 held | $0.00 | 07/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LGVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Logos Global Management LP | 0 % | 904.00 K | 1.29 M |
LGVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LGVN ranks across every disease it competes in
Competitive Position is a premium feature
See how LGVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLGVN News
LGVNLongeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron Inc. announced its participation in three upcoming longevity and aging investment conferences. The company is advancing its investigational product, laromestrocel, which has shown positive results in a Phase 2b trial for aging-related frailty. Additionally, Longeveron was awarded $1 million in the XPRIZE Healthspan competition, enhancing its funding prospects for future trials.
Read more →LGVN▼ -59.4%on this news
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announced that its ELPIS II Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome (HLHS) did not meet its primary endpoint. However, the treatment showed a favorable safety profile and potential benefits in exploratory outcomes. The company plans to discuss these results with the FDA to determine future steps.
Read more →LGVNLongeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Longeveron Inc. will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. The company focuses on developing cellular therapies for chronic aging-related conditions, with its lead product, laromestrocel, showing promise in various applications. Longeveron has received multiple FDA designations for its investigational therapies.
Read more →LGVN▼ -18.8%on this news
Longeveron Announces 1-for-10 Reverse Stock Split
Longeveron Inc. announced a 1-for-10 reverse stock split of its Class A and B common stock, effective August 26, 2026. This decision, approved by stockholders and the Board, aims to increase the share price to meet Nasdaq's minimum bid requirement. The company expects this structural adjustment to align better with institutional investor preferences and support its ongoing clinical programs.
Read more →LGVNLongeveron Appoints Nirav Jhaveri as Chief Financial Officer
Longeveron Inc. has appointed Nirav Jhaveri as Chief Financial Officer, succeeding Marie Washburn. Jhaveri, with over 25 years in capital markets and biotech, is expected to enhance the company's financial operations. Longeveron is advancing its stem cell therapy, laromestrocel, with a Phase 2b trial for HLHS results expected in September 2026.
Read more →LGVN▼ -6.6%on this news
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron Inc. reported its Q2 2026 financial results, highlighting progress in its Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome, with results expected in September. The company has been recognized in the XPRIZE Healthspan competition and appointed new independent directors. Despite a net loss increase, Longeveron remains focused on advancing its clinical programs.
Read more →LGVN▼ -6%on this newsshared move
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
Longeveron Inc. has been selected as a Milestone 2 Awardee in the XPRIZE Healthspan competition, receiving $1 million to advance its clinical trials. The company aims to develop therapies that significantly extend healthy life in adults aged 50-90. Laromestrocel, its lead product, has shown positive results in multiple clinical trials for various aging-related conditions.
Read more →LGVNLongeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Longeveron Inc. will report its second quarter financial results for 2026 on August 12, 2026, after market close. The company will also provide a business update during a conference call at 4:30 p.m. ET on the same day. Longeveron specializes in regenerative medicine and has several FDA designations for its lead product, laromestrocel.
Read more →LGVNDeborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Longeveron Inc. has elected Dr. Deborah D. Ascheim to its Board of Directors. Dr. Ascheim, a seasoned biotech executive, brings extensive experience in developing therapies for various diseases. Her appointment is expected to enhance Longeveron's efforts in advancing its stem cell therapy, laromestrocel, particularly for hypoplastic left heart syndrome, a serious pediatric condition.
Read more →LGVN▼ -6.5%on this news
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
Longeveron presented new clinical data at the 2026 AAIC, showing that its cellular therapy, laromestrocel, significantly reduces neuroinflammation in Alzheimer's patients. The results indicate a durable anti-inflammatory effect and potential blood biomarker correlates with clinical outcomes. The FDA has granted RMAT designation for laromestrocel, supporting its continued clinical development.
Read more →LGVNLongeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. has appointed Marie Washburn as Chief Financial Officer, effective July 13, 2026. Washburn, who has over 20 years of experience in the pharmaceutical and biotech sectors, previously served as Vice President and Corporate Controller at Longeveron. The company is focused on delivering results from its Phase 2b clinical trial for laromestrocel, a stem cell therapy for Hypoplastic Left Heart Syndrome, expected in Q3 2026.
Read more →LGVNLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron Inc. has received Small or Medium-sized Enterprise (SME) status from the European Medicines Agency (EMA). This designation provides the company with significant benefits, including access to scientific advice and reduced fees, which can enhance the chances of regulatory approval for its therapies. The SME program aims to support smaller companies in navigating the drug development process more effectively.
Read more →LGVNLongeveron to Present at BIO International Convention 2026
Longeveron Inc. will present at the BIO International Convention 2026, showcasing data on their stem cell therapy, laromestrocel. The company aims to establish partnerships for treating conditions like Hypoplastic Left Heart Syndrome and Alzheimer’s disease. They have reported positive results from clinical trials and anticipate further data from the Phase 2b ELPIS II trial in August 2026.
Read more →LGVNLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. has outlined its corporate strategy and key priorities for 2026 in a letter to stockholders. The company is focusing on its stem cell therapy, laromestrocel, and is preparing for significant milestones, including data from its Phase 2b clinical trial in Hypoplastic Left Heart Syndrome. Longeveron aims to enhance stockholder value through strategic partnerships and a capital-efficient model.
Read more →LGVNLongeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Inc. reported its first quarter financial results for 2026, highlighting a strategic repositioning to enhance shareholder value. The company anticipates top-line results from its Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome by August 2026. Additionally, Longeveron successfully closed a $30 million private placement to support its operations and development programs.
Read more →LGVNLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announced that the independent Data Monitoring Committee has completed its review of the Phase 2b clinical trial (ELPIS II) for laromestrocel, an adjunct therapy for hypoplastic left heart syndrome (HLHS). The DMC found no safety concerns and recommended continuing the trial as designed. Top-line results are expected in August 2026.
Read more →LGVNLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced a constructive Type C meeting with the FDA regarding its ELPIS II Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome (HLHS). The FDA acknowledged the significant unmet need for effective therapies but raised concerns about the trial's primary endpoint. Despite this, Longeveron is optimistic about future discussions and potential regulatory pathways following the trial's results, expected in August 2026.
Read more →LGVNLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Longeveron Inc. will report its first quarter financial results for 2026 and provide a business update on May 13, 2026. The company, focused on cellular therapies for critical health conditions, will host a conference call at 4:30 p.m. ET. The event will be accessible via webcast, with an archived replay available afterward.
Read more →LGVNLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Longeveron Inc. has announced the issuance of a patent by the China National Intellectual Property Administration for potency assay methods related to human mesenchymal stem cells (MSCs). This patent adds to the company's strong global patent portfolio, now totaling 52 patents, and secures rights until 2041. Longeveron's lead product, laromestrocel, is currently in clinical trials for various conditions, including hypoplastic left heart syndrome, with promising designations from the FDA that may facilitate its path to regulatory approval.
Read more →LGVN▲ +8.1%on this news
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron Inc. has reported its financial results for the year ending December 31, 2025, and provided an update on its business developments. The company is focusing on its pivotal Phase 2b clinical trial, ELPIS II, which evaluates laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS), with results expected in Q3 2026. Longeveron has successfully closed a $30 million private placement, enabling further advancements in its clinical programs. The company aims to leverage partnerships to optimize capital use and accelerate time-to-market for its therapies addressing serious pediatric and aging-related conditions.
Read more →About Longeveron Inc.
Headquarters1951 NW 7TH AVENUE, MIAMI, FL, 33136
BIOPHARMAWATCH ELITE PLUS
Trade the next LGVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime